For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

Concurrent Session: Variables impacting outcomes after IEC
Friday, September 8, 2023 01:45 PM - 02:45 PM  
Grand Ballroom L
Chair
Kevin Curran, MD, Memorial Sloan Kettering Cancer Center, USA

Speakers
Kevin Curran, MD, Memorial Sloan Kettering Cancer Center, USA – Patient Related Variables Impacting Outcome following Immune Effector Cell (IEC) therapy
Sarah Nikiforow, MD, PhD, Dana-Farber Cancer Institute, USA – Unknown Impacts of IEC Product Composition and Variability
Regina Myers, MD, Children's Hospital of Philadelphia, USA – Post-infusion Variables Impacting Outcomes After CAR T-cell Therapy for B-ALL


Lymphodepletion (including PK/exposure), cell dose/product composition, and clinical variables impacting outcomes will be discussed

Session Objectives
  1. Discuss impact of pre-infusion and patient variables on outcomes following IEC therapy.
  2. Outline the impact of cell therapy product variability and production methodology on patient outcome following IEC therapy.
  3. Explore opportunities for monitoring and interventions following IEC therapy to impact outcome/durability of IEC therapy. 

Kevin Curran MD
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
Chair and Speaker


Regina Myers MD
Assistant Professor of Pediatrics
Children's Hospital of Philadelphia
Speaker


Sarah Nikiforow MD, PhD
Asst Professor, Stem Cell Transplantation Program, Asst. Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Program
Dana-Farber Cancer Institute
Speaker